KSQ Therapeutics is a Massachusetts-based biotechnology company focused on discovering and developing transformative medicines using precision genomics. Leveraging their proprietary CRISPRomics® platform, they aim to identify top therapeutic targets with curative potential. Their core mission is to tackle the toughest challenges in medicine, particularly in cancer treatment, through advanced CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) programs.
KSQ Therapeutics has made significant strides in the biotech industry, advancing a robust pipeline of first-in-class candidates and partnered programs. Their innovative approach has positioned them as a leader in precision functional genomics, contributing to the development of potentially curative therapies. Their work has garnered attention and support from notable investors and industry leaders, reinforcing their impact on the future of medicine.
